Top Page
Spire Healthcare
(LSE:SPI)
Spire Healthcare (SPI) vs. iShares MSCI United Kingdom ETF (EWC)
Spire Healthcare Business Overview & Revenue Model
Spire Healthcare Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.51B | 1.36B | 1.20B | 1.11B | 919.90M | Gross Profit |
| 683.60M | 520.60M | 440.50M | 394.10M | 361.80M | EBIT |
| 137.50M | 126.50M | 104.20M | 81.20M | 69.00M | EBITDA |
| 250.40M | 231.20M | 202.10M | 182.20M | -51.90M | Net Income Common Stockholders |
| 25.40M | 27.30M | 8.60M | -9.70M | -233.90M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 43.70M | 49.60M | 74.20M | 202.60M | 106.30M | Total Assets |
| 2.34B | 2.29B | 2.16B | 2.24B | 2.10B | Total Debt |
| 1.28B | 1.26B | 1.19B | 1.27B | 1.17B | Net Debt |
| 1.24B | 1.21B | 1.12B | 1.06B | 1.06B | Total Liabilities |
| 1.60B | 1.55B | 1.43B | 1.53B | 1.40B | Stockholders Equity |
| 748.40M | 739.90M | 731.00M | 709.60M | 706.60M |
| Cash Flow | Free Cash Flow | |||
| 123.60M | 115.50M | 72.80M | 101.30M | 95.10M | Operating Cash Flow |
| 235.70M | 199.90M | 160.50M | 170.60M | 141.70M | Investing Cash Flow |
| -99.00M | -157.20M | -98.00M | -48.30M | -46.40M | Financing Cash Flow |
| -145.10M | -82.90M | -190.90M | -26.00M | -79.80M |
Spire Healthcare Technical Analysis
Spire Healthcare Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £849.00M | 33.49 | 3.41% | 1.09% | 11.20% | -6.80% | |
72 Outperform | £463.76M | 64.95 | 2.93% | 1.14% | 40.66% | -55.09% | |
69 Neutral | £702.13M | 60.17 | 4.50% | 2.69% | 6.74% | 54.83% | |
65 Neutral | £333.86M | 8.82 | 11.74% | ― | 38.80% | ― | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
53 Neutral | £471.71K | ― | -3.66% | ― | -23.61% | -30.61% |
Spire Healthcare Corporate Events
Spire Healthcare Group PLC has announced a change in its major holdings, with FIL Limited acquiring or disposing of voting rights and financial instruments. The transaction resulted in FIL Limited holding 9.105% of the voting rights in Spire Healthcare. This change in holdings could impact the company’s governance and influence decision-making processes, potentially affecting stakeholders and market perceptions.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC announced the successful passage of all resolutions at its 2025 Annual General Meeting, held on May 14, 2025. The results indicate strong shareholder support, with most resolutions receiving near-unanimous approval. This outcome reflects positively on the company’s governance and may enhance its position in the healthcare sector, potentially influencing investor confidence and future strategic decisions.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC reported that its performance from January to April 2025 aligned with expectations and the 2025 guidance, with a transformation program on track to deliver significant efficiencies. The company, which has full UK revenue exposure, does not foresee any major cost or supply chain issues due to recent tariff announcements. Additionally, Spire Healthcare has been named a founding supplier in the Government’s National Strategic Supplier Relationship programme, enhancing its collaboration with the NHS for sustainable NHS commissioning.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC announced that its Executive Directors, Justin Ash and Harbant Samra, have exercised their vested Executive Share Plan awards. Justin Ash exercised both his Long Term Incentive Plan and Deferred Share Bonus Plan awards, retaining a significant number of shares after tax satisfaction, while Harbant Samra exercised his Long Term Incentive Plan award, also retaining shares. This move reflects the directors’ confidence in the company’s future and their commitment to its growth, potentially impacting stakeholder perceptions positively.
Spire Healthcare Group plc has published its 2024 Annual Report and 2025 Notice of Annual General Meeting, with documents available on its website and the National Storage Mechanism. The company encourages shareholders to attend the AGM on 14 May 2025 in London and submit questions via email, with resolutions and voting results to be shared post-meeting. This announcement underscores Spire Healthcare’s commitment to transparency and shareholder engagement, potentially strengthening its market position and stakeholder trust.
Spire Healthcare has announced the acquisition of Acorn Occupational Health Limited for an initial consideration of £3.3 million, aiming to expand its footprint in the Occupational Health Services sector. This acquisition is part of Spire’s strategy to grow its Primary Care Business, which saw a 15% revenue increase in 2024, and is expected to enhance Spire’s ability to secure nationwide contracts and support organic growth, with the Occupational Health market in the UK valued at £1.5-2 billion and growing at 6% annually.
Spire Healthcare Group PLC has announced the grant of Long Term Incentive Plan (LTIP) awards to its Executive Directors, Justin Ash and Harbant Samra, with performance share awards over the company’s ordinary shares. These awards, representing 200% of their current base salary, are contingent upon meeting specific performance conditions related to shareholder return, ROCE, hospital EBIT margin, and operational excellence. This move aims to align the directors’ interests with those of shareholders and drive the company’s performance over the coming years.
Spire Healthcare Group PLC announced the grant of Deferred Share Bonus Plan (DSBP) awards to its Executive Directors, requiring them to defer a portion of their 2024 bonuses into company shares for three years. This move aligns the interests of the management with shareholders and is expected to enhance long-term company performance by incentivizing key executives.